Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

2934 - Differential expression of circulating miR375 and miR371 to detect teratoma and viable germ cell malignancy


30 Sep 2019


Poster Display session 3


Tumour Site

Genitourinary Cancers


Lucia Nappi


Annals of Oncology (2019) 30 (suppl_5): v356-v402. 10.1093/annonc/mdz249


L. Nappi1, M. Thi2, B.J. Eigl3, K.N. Chi4, M.E. Gleave5, A. So2, P.C. Black2, R. Hamilton6, S. Daneshmand7, C.R. Nichols8, C.K. Kollmannsberger3

Author affiliations

  • 1 Medical Oncology, British Columbia Cancer Agency, V5Z 4E6 - Vancouver/CA
  • 2 Urologic Sciences, Vancouver Prostate Centre, V6H 3Z6 - Vancouver/CA
  • 3 Medical Oncology Department, BC Cancer Agency - Vancouver, V5Z 4E6 - Vancouver/CA
  • 4 Medical Oncology, BC Cancer Agency - Vancouver, V5Z 4E6 - Vancouver/CA
  • 5 Urologic Sciences, University of British Columbia Faculty of Medicine, V6T 1Z3 - Vancouver/CA
  • 6 Urology, Princess Margaret Cancer Centre, M5G2C4 - Toronto/CA
  • 7 Urology, University of South California, 90089 - Los Angeles/US
  • 8 Urology, Testicular Cancer Commons, nnn - New York/US


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 2934


MicroRNAs are examined for clinical utility in active germ cell malignancies (GCM). miR-371a-3p (miR371) has a very high specificity and high sensitivity for the detection of GCM. However, in teratoma neither tissue nor serum/plasma are miR371 positive. miR375 is overexpressed in teratoma tissue, but detectability in blood and its utility is unknown.


GCM patients (pts) enrolled from 10-2016 to 03-2019 in the GU biobank program at British Columbia Cancer were analyzed for plasma miR371/miR375 expression by RT-PCR and quantified by ΔΔCT method. Spike-in cel-miR-39-3p, miR-451 and miR-30b-5p were used as quality/internal controls. Sensitivity, specificity, PPV, NPV, AUC of the ROC of miR375 in detecting teratoma were analyzed.


miR375 expression was measured in 69 pts of whom 15 (22%) had pathologically confirmed residual teratoma post-chemotherapy, 4 (6%) residual post-chemotherapy mass without teratoma, 8 (11%) no evidence of residual disease post-chemotherapy, 15 (22%) metastatic seminoma and 27 (39%) CSI with no evidence of tumor. miR375 expression was significantly higher in pts with residual teratoma-post chemotherapy than in non-teratoma (p < 0.0001). Concurrent miR371 and miR375 expression was evaluated in 17 pts with metastatic nonseminoma prior to and post-chemotherapy. miR371 correlated with viable GCM and disappeared after chemotherapy in all but one pt (presenting residual choriocarcinoma). Post-chemotherapy miR375 was unchanged or increased from pre-chemotherapy samples in 85% of pts with pathologically confirmed post-chemotherapy teratoma and remained low in 90% of patients with either complete response or non-teratoma after chemotherapy. Sensitivity of miR375 was 93% (95% CI: 68-99), specificity 75% (95% CI: 43-95), NPV 90% (95% CI 95%: 57-98), PPV 82% (CI 95%: 63-93) and the AUC of miR375 in the post-chemotherapy setting was 0.93 (95% CI: 0.83-1.0; p < 0.0001).


miR375 is overexpressed and detectable in the plasma of pts with teratoma while its expression is significantly lower in nonseminoma pts without teratoma or in seminoma. The evaluation of miR371/miR375 may be clinically useful to guide therapeutic decisions (surgery or chemotherapy). Larger studies are warranted.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.